CONTRAD SWISS is a dynamic Swiss-based pharmaceutical corporation revolutionizing the regenerative medicine landscape.
Headquartered in Lugano, Contrad Swiss is the owner of proprietary SIGMOLECS® Technology which takes the current use of peptides as active ingredients a giant step forward. The company portfolio comprises medical devices and aesthetic products, positioned in the premium segment, delivering unparalleled value.
SIGMOLECS®  is a unique technology guiding cell behaviour for a wide range of treatments. It talks to cells in their own language, enabling more effective therapies.
It is designed to work with various treatment methods, following the body's natural systems and also enhancing the penetration of other important molecules.
This breakthrough technology, utilizing customized peptide sequences, is the driving force behind our specialized non-invasive product lines in Orthopaedics (500Line), Aesthetic Medicine (ACTV8 PRO), and in our targeted alleviating lotion (Egyfil), all supported by recently published peer-reviewed studies.
The 500Line, powered by SIGMOLECS®, addresses unmet clinical needs in osteoarthritis and connective tissue pathology through non-invasive, rapid-acting formulations. Egyfil offers targeted relief for muscle & joint stiffness and discomfort. ACTV8 PRO is designed for regenerative aesthetic physicians. 
CONTRAD SWISS is signaling the future of regenerative medicine.

Pharmaceutical

Biotechnology

Medical Devices

CONTRAD SWISS

Org chart

Teams

Similar companies